These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27738988)

  • 1. Prophylactic Hepatitis E Vaccine.
    Zhang J; Zhao Q; Xia N
    Adv Exp Med Biol; 2016; 948():223-246. PubMed ID: 27738988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Hepatitis E Vaccine.
    Zhang J; Zheng Z; Xia N
    Adv Exp Med Biol; 2023; 1417():227-245. PubMed ID: 37223870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward the development of a hepatitis E vaccine.
    Kamili S
    Virus Res; 2011 Oct; 161(1):93-100. PubMed ID: 21620908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prophylactic vaccines for hepatitis type E].
    Liu C; Zheng ZZ; Xia NS
    Zhonghua Gan Zang Bing Za Zhi; 2023 May; 31(5):477-482. PubMed ID: 37365023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from hepatitis E vaccine design.
    Li S; Zhang J; Xia N
    Curr Opin Virol; 2015 Apr; 11():130-6. PubMed ID: 25913817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel linear neutralizing epitope of hepatitis E virus.
    Tang ZM; Tang M; Zhao M; Wen GP; Yang F; Cai W; Wang SL; Zheng ZZ; Xia NS
    Vaccine; 2015 Jul; 33(30):3504-11. PubMed ID: 26051517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity difference between two hepatitis E vaccines derived from genotype 1 and 4.
    Wen J; Behloul N; Dai X; Dong C; Liang J; Zhang M; Shi C; Meng J
    Antiviral Res; 2016 Apr; 128():36-42. PubMed ID: 26850829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years.
    Yu XY; Chen ZP; Wang SY; Pan HR; Wang ZF; Zhang QF; Shen LZ; Zheng XP; Yan CF; Lu M; Chen B; Zheng Y; Zhang J; Lv HK; Huang SJ
    Vaccine; 2019 Jul; 37(32):4581-4586. PubMed ID: 31262585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of a recombinant hepatitis E vaccine HEV 239.
    Li SW; Zhao Q; Wu T; Chen S; Zhang J; Xia NS
    Hum Vaccin Immunother; 2015; 11(4):908-14. PubMed ID: 25714510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity.
    Zhang J; Li SW; Wu T; Zhao Q; Ng MH; Xia NS
    Rev Med Virol; 2012 Sep; 22(5):339-49. PubMed ID: 22645002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy.
    Sridhar S; Situ J; Cai JP; Yip CC; Wu S; Zhang AJ; Wen L; Chew NF; Chan WM; Poon RW; Chan JF; Tsang DN; Chen H; Xia NS; Yuen KY
    J Hepatol; 2021 Jun; 74(6):1315-1324. PubMed ID: 33845058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of different geographic strains of the hepatitis E virus with anti-hepatitis E virus-positive serum samples obtained from different sources.
    Meng J; Pillot J; Dai X; Fields HA; Khudyakov YE
    Virology; 1998 Sep; 249(2):316-24. PubMed ID: 9791023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
    Zhang X; Wei M; Sun G; Wang X; Li M; Lin Z; Li Z; Li Y; Fang M; Zhang J; Li S; Xia N; Zhao Q
    Vaccine; 2016 Nov; 34(48):5871-5877. PubMed ID: 27793484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel multi-epitope peptide vaccine candidate targeting hepatitis E virus: An in silico approach.
    Kumar A; Sahu U; Agnihotri G; Dixit A; Khare P
    J Viral Hepat; 2024 Aug; 31(8):446-456. PubMed ID: 38727597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression, purification and immunogenicity of a novel hepatitis E virus-like particle].
    Dong C; Meng JH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 May; 22(3):339-42. PubMed ID: 16643795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of autophagy induction on HEV 239 vaccine immune response in a mouse model.
    Khateri M; Abdoli A; Motevalli F; Fotouhi F; Bolhassani A; Arashkia A; Jazaeri EO; Shahbazi S; Mehrbod P; Naziri H; Aghasadeghi MR
    IUBMB Life; 2018 Mar; 70(3):207-214. PubMed ID: 29369472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the Production of Virus-Like Particles for Vaccination against Hepatitis E Virus.
    Mazalovska M; Kouokam JC
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32751441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.
    Renoux VM; Fleury MJ; Bousarghin L; Gaitan J; Sizaret PY; Touzé A; Coursaget P
    Vaccine; 2008 Dec; 26(51):6602-7. PubMed ID: 18835319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Antigenicity of Rabbit Hepatitis E Virus-Like Particles Produced by Recombinant Baculoviruses.
    Bai H; Kataoka M; Ami Y; Suzaki Y; Takeda N; Muramatsu M; Li TC
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial.
    Zhu FC; Zhang J; Zhang XF; Zhou C; Wang ZZ; Huang SJ; Wang H; Yang CL; Jiang HM; Cai JP; Wang YJ; Ai X; Hu YM; Tang Q; Yao X; Yan Q; Xian YL; Wu T; Li YM; Miao J; Ng MH; Shih JW; Xia NS
    Lancet; 2010 Sep; 376(9744):895-902. PubMed ID: 20728932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.